Searchable abstracts of presentations at key conferences in endocrinology

ea0080p4 | Abstracts | UKINETS2021

The Impact of the Covid-19 Pandemic on Neuroendocrine (NET) services and patients: A quantitative and qualitative analysis

Seneviratne Dilini , Walsh Emma , Finnen John , Munir Alia

Introduction: The response to SARS-CoV-2 lead to interventions to mitigate the pandemic. We retrospectively analysed the effect of changes on key NET services. These included: change in clinic media, absolute change in numbers for endoscopy and bronchoscopy, nuclear imaging, SSA administration and PRRT numbers compared with 2019.Method: The NET database was analysed. Endoscopy rates on a monthly basis were reviewed. Two bespoke postal patient surveys wer...

ea0077p36 | Endocrine Cancer and Late Effects | SFEBES2021

The Impact of COVID-19 on Endocrine Treatments from a Neuroendocrine (NET) patient perspective: homecare and self-injection

Walsh Emma , Ravindiran Abiramie , Paramore Jane , Bates Suzanna , Ibbotson Vicky , Dunkley Kay , Munir Alia

Introduction: The global impact of COVID-19 has been unprecedented. Specific recommendations for the management of neuroendocrine disorders in the pandemic were rapidly released by Endocrine experts. To comply with COVID rules, NET patients, due to attend the endocrine unit in March 2020 for Somatostatin analogue therapy, were rapidly identified. 25 vulnerable patients had urgent domiciliary administration arranged. Other patients were taught to self-inject. Postal surveys wer...

ea0077p246 | Reproductive Endocrinology | SFEBES2021

The Impact of COVID-19 on Endocrine Treatments from a patient perspective - effect on parenteral testosterone

Walsh Emma , Bates Suzanna , Dunkley Kay , Paramore Jane , Ibbotson Vicky , Munir Alia

Introduction: The COVID-19 pandemic has had a huge impact on the delivery of health services. Here we review the patient perspective, on rapid changes in treatment delivery of testosterone preparations instituted in the first wave of the pandemic.Methods: 49 hypogonadal male patients were identified as attenders to the Endocrine unit for Nebido™ injection. They were temporarily switched to testosterone gel to rapidly comply with COVID rules. 8 weeks...